0001415889-17-000282.txt : 20170216
0001415889-17-000282.hdr.sgml : 20170216
20170216190635
ACCESSION NUMBER: 0001415889-17-000282
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170214
FILED AS OF DATE: 20170216
DATE AS OF CHANGE: 20170216
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001070494
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 061376651
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3611 VALLEY CENTRE DRIVE
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 858-558-2871
MAIL ADDRESS:
STREET 1: 3611 VALLEY CENTRE DRIVE
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Moore Terrence O
CENTRAL INDEX KEY: 0001454276
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50768
FILM NUMBER: 17619385
MAIL ADDRESS:
STREET 1: C/O ACADIA PHARMACEUTICALS INC
STREET 2: 3911 SORRENTO VALLEY BLVD
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
form4-02162017_040225.xml
X0306
4
2017-02-14
0001070494
ACADIA PHARMACEUTICALS INC
ACAD
0001454276
Moore Terrence O
3611 VALLEY CENTRE DRIVE, SUITE 300
SAN DIEGO
CA
92130
false
true
false
false
EVP, CHIEF COMMERCIAL OFFICER
Common Stock
2017-02-14
4
M
0
87128
19.61
A
90759
D
Common Stock
2017-02-14
4
S
0
89088
39.6863
D
1671
D
Common Stock
2017-02-15
4
M
0
1700
19.61
A
3371
D
Common Stock
2017-02-15
4
S
0
1700
39.65
D
1671
D
Common Stock
2017-02-16
4
M
0
17421
19.61
A
19092
D
Common Stock
2017-02-16
4
M
0
19687
27.20
A
38779
D
Common Stock
2017-02-16
4
M
0
29644
34.45
A
68423
D
Common Stock
2017-02-16
4
S
0
66752
39.8807
D
1671
D
Stock Option (right to buy)
19.61
2017-02-14
4
M
0
12747
0
D
2023-08-18
Common Stock
12747
7649
D
Stock Option (right to buy)
19.61
2017-02-14
4
M
0
74381
0
D
2023-08-18
Common Stock
74381
55223
D
Stock Option (right to buy)
19.61
2017-02-15
4
M
0
1700
0
D
2023-08-18
Common Stock
1700
53523
D
Stock Option (right to buy)
19.61
2017-02-16
4
M
0
17421
0
D
2023-08-18
Common Stock
17421
36102
D
Stock Option (right to buy)
27.20
2017-02-16
4
M
0
19687
0
D
2024-03-06
Common Stock
19687
13125
D
Stock Option (right to buy)
34.35
2017-02-16
4
M
0
29644
0
D
2025-03-19
Common Stock
29644
90356
D
Includes 717, 1,243, 461 and 1,210 shares acquired in November 2014, May 2015, November 2015 and May 2016, respectively, by Mr. Moore under the ACADIA Pharmaceuticals Employee Stock Purchase Plan, as amended.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2015, as amended in June 2016.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $39.72 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $39.65 to $40.38 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
25% of the shares subject to the Stock Option vested and became exercisable on August 19, 2014. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.
25% of the shares subject to the Stock Option vested and became exercisable on March 7, 2015. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.
25% of the shares subject to the Stock Option vested and became exercisable on March 20, 2016. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.
/s/ Elizabeth Carter, Attorney-in-Fact
2017-02-16